AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28801235 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic frailty screening instrument followed by standard GP care
Number of subjects: 3092
Study 28801235 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic frailty screening instrument followed by nurse-led care program
Number of subjects: 3092
Study 28801235 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3092
Study 28801235 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening plus nurse-led care
Number of subjects: 3092
Study 25222800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBTI‐BP; n = 17)
Number of subjects: 30
Study 25222800 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE; n = 13)
Number of subjects: 30
Study 23780458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography (esophageal or endobronchial ultrasonography) with aspiration of intrathoracic lymph nodes
Number of subjects: 304
Study 23780458 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy with transbronchial and endobronchial lung biopsies
Number of subjects: 304
Study 23780458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage
Number of subjects: 304
Study 23780458 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 304
Study 23780458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography
Number of subjects: 304
Study 21075378 — intervention group
Group type: EXPERIMENTAL
Intervention: One-incision modified Watson-Jones approach
Number of subjects: 26
Study 21075378 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-incision approach
Number of subjects: 26
Study 21075378 — intervention group
Group type: COMPARATOR
Intervention: THA subjects (combined group)
Number of subjects: 26
Study 19709502 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/d of eicosapentaenoic acid (EPA) for 8 weeks
Number of subjects: 57
Study 19709502 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 57
Study 17287149 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=87)
Number of subjects: 173
Study 17287149 — intervention group
Group type: COMPARATOR
Intervention: Stretching-control group (n=86)
Number of subjects: 173
Study 12694639 — intervention group
Group type: EXPERIMENTAL
Intervention: Midcycle assessment in NC women
Number of subjects: 54
Study 12694639 — intervention group
Group type: EXPERIMENTAL
Intervention: Midcycle assessment in OC women
Number of subjects: 54
Study 12694639 — intervention group
Group type: EXPERIMENTAL
Intervention: All cycle phases in OC women and participants not in intimate relationships
Number of subjects: 54
Study 12694639 — intervention group
Group type: EXPERIMENTAL
Intervention: All cycle phases in men and single women
Number of subjects: 54
Study 12694639 — intervention group
Group type: EXPERIMENTAL
Intervention: All cycle phases in engaged women
Number of subjects: 54
Study 12694639 — intervention group
Group type: EXPERIMENTAL
Intervention: All cycle phases in men
Number of subjects: 54
Study 12694639 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase in NC women
Number of subjects: 54
Study 10571599 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-207266-A (20 mg)
Number of subjects: 18
Study 10571599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8768852 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10(‐4) mol/L)
Number of subjects: 33
Study 8768852 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (10(‐4) mol/L)
Number of subjects: 33
Study 8768852 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 33
Study 1993796 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 10
Study 1993796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6761905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (20mg/kg body-weight)
Number of subjects: 91
Study 6761905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 91
Study 30335419 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week mindfulness training program
Number of subjects: 60
Study 30335419 — intervention group
Group type: COMPARATOR
Intervention: Half-day mindfulness training seminar
Number of subjects: 60
Study 28511794 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sampling method (distal end of the epidural catheter)
Number of subjects: 86
Study 28511794 — intervention group
Group type: COMPARATOR
Intervention: Traditional sampling method (proximal end of the epidural catheter)
Number of subjects: 86
Study 25582924 — intervention group
Group type: COMPARATOR
Intervention: Standard number of waves/session (mean 2858.3±302.8) using Dornier lithotripter U/15/50
Number of subjects: 332
Study 25582924 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded number of waves/session (mean 6728.9±889.6) using Siemens Modularis lithotripter
Number of subjects: 332
Study 24244335 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents (BES)
Number of subjects: 11015
Study 24244335 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer drug-eluting stents (DES)
Number of subjects: 11015
Study 22111914 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with fast track perioperative treatment and Xelox chemotherapy
Number of subjects: 340
Study 22111914 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery with fast track perioperative treatment and Xelox chemotherapy
Number of subjects: 340
Study 22111914 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with conventional perioperative treatment and mFolfox6 chemotherapy
Number of subjects: 340
Study 22111914 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery with conventional perioperative treatment and mFolfox6 chemotherapy
Number of subjects: 340
Study 19395457 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 x 9 mg/kg)
Number of subjects: 24
Study 19395457 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (i.v.)
Number of subjects: 24
Study 19395457 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept
Number of subjects: 24
Study 19395457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16467018 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg or 50 mg twice weekly (BIW) or 25 mg once weekly
Number of subjects: 0
Study 16467018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (original placebo patients received 25 mg BIW for the final 12 weeks of the double‐blind period)
Number of subjects: 0
Study 14748943 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised, dispersible ferric pyrophosphate (5 mg Fe) in infant cereal
Number of subjects: 20
Study 14748943 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (5 mg Fe) in infant cereal
Number of subjects: 20
Study 14748943 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised, dispersible ferric pyrophosphate (5 mg Fe) in yoghurt drink
Number of subjects: 20
Study 14748943 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (5 mg Fe) in yoghurt drink
Number of subjects: 20
Study 10627323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rally drivers
Number of subjects: 18
Study 10627323 — intervention group
Group type: COMPARATOR
Intervention: Reference group (population sample)
Number of subjects: 18
Study 9369270 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 5.0 ng Ang II x kg(‐1) x min(‐1) (pressor dose)
Number of subjects: 19
Study 9369270 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 1.0 ng Ang II x kg(‐1) x min(‐1) (subpressor dose)
Number of subjects: 19
Study 9369270 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of Ang II during oral glucose tolerance test
Number of subjects: 19
Study 1572493 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (laparoscopy)
Number of subjects: 105
Study 1572493 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (control)
Number of subjects: 105
Study 3883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin 2.4 million U weekly for three weeks (total 7.2 million U)
Number of subjects: 20
Study 3883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous penicillin G 20 million U a day for 10 days
Number of subjects: 20
Study 3883177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 30636561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prasugrel (5 mg daily)
Number of subjects: 0
Study 30636561 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 0
Study 30547863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sous vide preparation of pork roast from an organic farm
Number of subjects: 11
Study 30547863 — intervention group
Group type: COMPARATOR
Intervention: Oven cooking of pork roast from an organic farm
Number of subjects: 11
Study 30547863 — intervention group
Group type: COMPARATOR
Intervention: Sous vide preparation of pork roast from an ordinary pig
Number of subjects: 11
Study 30547863 — intervention group
Group type: COMPARATOR
Intervention: Oven cooking of pork roast from an ordinary pig
Number of subjects: 11
Study 28838480 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Expanding Stent (SE)
Number of subjects: 660
Study 28838480 — intervention group
Group type: COMPARATOR
Intervention: Balloon-Expandable Stent (BE)
Number of subjects: 660
Study 26633806 — intervention group
Group type: EXPERIMENTAL
Intervention: CTZ (Chemotherapy + Zoledronic Acid)
Number of subjects: 188
Study 26633806 — intervention group
Group type: COMPARATOR
Intervention: CT (Chemotherapy)
Number of subjects: 188
Study 26633806 — intervention group
Group type: EXPERIMENTAL
Intervention: CTZ (Chemotherapy + Zoledronic Acid) in postmenopausal patients
Number of subjects: 188
Study 26633806 — intervention group
Group type: COMPARATOR
Intervention: CT (Chemotherapy) in postmenopausal patients
Number of subjects: 188
Study 26633806 — intervention group
Group type: EXPERIMENTAL
Intervention: CTZ (Chemotherapy + Zoledronic Acid) in triple-negative breast cancer patients
Number of subjects: 188
Study 26633806 — intervention group
Group type: COMPARATOR
Intervention: CT (Chemotherapy) in triple-negative breast cancer patients
Number of subjects: 188
Study 23403043 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based recruitment via Google advertising
Number of subjects: 1699
Study 23403043 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based recruitment through trustworthy organizations and websites
Number of subjects: 1699
Study 23403043 — intervention group
Group type: COMPARATOR
Intervention: Less effective recruitment techniques
Number of subjects: 1699
Study 21377179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 48
Study 21377179 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 48
Study 21377179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (aerobic and resistance)
Number of subjects: 48
Study 21377179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 48
Study 18644036 — intervention group
Group type: EXPERIMENTAL
Intervention: almotriptan 12.5 mg combined with aceclofenac 100 mg
Number of subjects: 112
Study 18644036 — intervention group
Group type: COMPARATOR
Intervention: triptan-placebo
Number of subjects: 112
Study 17176279 — intervention group
Group type: EXPERIMENTAL
Intervention: IM carbetocin (100 microgram)
Number of subjects: 329
Study 17176279 — intervention group
Group type: COMPARATOR
Intervention: IM syntometrine (1 ml, a mixture of 5 iu oxytocin and 0.5 mg ergometrine)
Number of subjects: 329
Study 17176279 — intervention group
Group type: EXPERIMENTAL
Intervention: IM carbetocin
Number of subjects: 329
Study 14971608 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative DRF >= 30% (group I, n=22)
Number of subjects: 32
Study 14971608 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative DRF < 30% (group II, n=10)
Number of subjects: 32
Study 14971608 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative drainage half-time
Number of subjects: 32
Study 14971608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean DRF preoperative
Number of subjects: 32
Study 14971608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean DRF postoperative
Number of subjects: 32
Study 10761802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (Group 1)
Number of subjects: 48
Study 10761802 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (Group 2)
Number of subjects: 48
Study 9709272 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening (four mammographic examinations at two-year intervals and seven annual clinical examinations)
Number of subjects: 21774
Study 9709272 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier screening (before age 50)
Number of subjects: 21774
Study 8454464 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (two sessions at weeks 1 and 2, follow-up at week 5)
Number of subjects: 137
Study 8454464 — intervention group
Group type: COMPARATOR
Intervention: Control group (theory analysis presentation)
Number of subjects: 137
Study 3779343 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg‐1)
Number of subjects: 12
Study 3779343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (225 mg methylcellulose)
Number of subjects: 12
Study 29757933 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity and support for healthy eating
Number of subjects: 650
Study 29757933 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard physical education curriculum)
Number of subjects: 650
Study 27903564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention based on a discussion informed by responses to the MAQ, Beliefs about Medicines Questionnaire‐Specific and Brief Illness Perception Questionnaire.
Number of subjects: 120
Study 27903564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tailored intervention).
Number of subjects: 120
Study 23953392 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the WOMAC questionnaire
Number of subjects: 53
Study 23953392 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the WOMAC questionnaire
Number of subjects: 53
Study 23953392 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the SF-12 questionnaire (PCS)
Number of subjects: 53
Study 23953392 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the SF-12 questionnaire (PCS)
Number of subjects: 53
Study 23953392 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the SF-12 questionnaire (MCS)
Number of subjects: 53
Study 23953392 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the SF-12 questionnaire (MCS)
Number of subjects: 53
Study 21719357 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month behavioral intervention
Number of subjects: 36
Study 21719357 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 36
Study 21110503 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic eye drops, used 4 times a day for 5 days before surgery
Number of subjects: 0
Study 21110503 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic eye drops, used 4 times a day for 5 days before surgery
Number of subjects: 0
Study 21110503 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 0
Study 18054894 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-Values Protocol
Number of subjects: 30
Study 18054894 — intervention group
Group type: COMPARATOR
Intervention: CONT-Values Protocol
Number of subjects: 30
Study 18054894 — intervention group
Group type: COMPARATOR
Intervention: No-Values Protocol
Number of subjects: 30
Study 18054894 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT with Coping Strategy (Defusion)
Number of subjects: 30
Study 18054894 — intervention group
Group type: COMPARATOR
Intervention: CONT with Coping Strategy (Suppression)
Number of subjects: 30
Study 15919047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low traffic condition (afternoon session)
Number of subjects: 36
Study 15919047 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy traffic condition (evening session)
Number of subjects: 36
Study 15919047 — intervention group
Group type: COMPARATOR
Intervention: Low traffic condition (evening session)
Number of subjects: 36
Study 15919047 — intervention group
Group type: COMPARATOR
Intervention: Heavy traffic condition (afternoon session)
Number of subjects: 36
Study 12504048 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus TAM
Number of subjects: 86
Study 12504048 — intervention group
Group type: COMPARATOR
Intervention: TAM alone
Number of subjects: 86
Study 10812042 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2/65% O2 challenge
Number of subjects: 50
Study 10812042 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (matched for age and gender)
Number of subjects: 50
Study 7855383 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and nicotinamide (3 g/day for 1 year)
Number of subjects: 21
Study 7855383 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 21
Study 2671502 — intervention group
Group type: EXPERIMENTAL
Intervention: MALG (antilymphoblast globulin)
Number of subjects: 42
Study 2671502 — intervention group
Group type: COMPARATOR
Intervention: ATGAM (antithymocyte globulin)
Number of subjects: 42
Study 1018027 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient rest in bed (IP) for six months followed by out-patient treatment
Number of subjects: 350
Study 1018027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory out-patient treatment (OP) from the start
Number of subjects: 350
Study 1018027 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient treatment with a plaster-of-Paris jacket (J) for nine months
Number of subjects: 350
Study 1018027 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory treatment without any support (No J)
Number of subjects: 350
Study 1018027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with PAS and isoniazid for eighteen months supplemented with streptomycin for the first three months (SPH)
Number of subjects: 350
Study 1018027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with PAS and isoniazid for eighteen months without the supplement (PH)
Number of subjects: 350
Study 31033046 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL flush volume
Number of subjects: 55
Study 31033046 — intervention group
Group type: COMPARATOR
Intervention: 3 mL flush volume
Number of subjects: 55
Study 31033046 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hourly flushing frequency
Number of subjects: 55
Study 31033046 — intervention group
Group type: COMPARATOR
Intervention: 24 hourly flushing frequency
Number of subjects: 55
Study 30728037 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical workforce (number of surgical, anesthetic, and obstetric physician providers)
Number of subjects: 3014
Study 30728037 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional referral hospitals
Number of subjects: 3014
Study 30728037 — intervention group
Group type: COMPARATOR
Intervention: General hospitals
Number of subjects: 3014
Study 30728037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean sections
Number of subjects: 3014
Study 29116299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Molar EasyMix (3M ESPE)
Number of subjects: 117
Study 29116299 — intervention group
Group type: COMPARATOR
Intervention: Vitro Molar (DFL)
Number of subjects: 117
Study 29116299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 117
Study 26363970 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (LRZ)
Number of subjects: 27
Study 26363970 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 27
Study 23100191 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 52
Study 23100191 — intervention group
Group type: COMPARATOR
Intervention: Mini-incision release
Number of subjects: 52
Study 20606150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (systolic BP < 130 mm Hg)
Number of subjects: 6400
Study 20606150 — intervention group
Group type: COMPARATOR
Intervention: Usual control (systolic BP 130 mm Hg to < 140 mm Hg)
Number of subjects: 6400
Study 20606150 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled (systolic BP ≥ 140 mm Hg)
Number of subjects: 6400
Study 20606150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 6400
Study 20606150 — intervention group
Group type: COMPARATOR
Intervention: Usual control
Number of subjects: 6400
Study 20606150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (extended follow-up)
Number of subjects: 6400
Study 20606150 — intervention group
Group type: COMPARATOR
Intervention: Usual control (extended follow-up)
Number of subjects: 6400
Study 18202964 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined conjugated estrogens (CE)/medroxyprogesterone acetate (MPA) at doses of 0.625/2.5 mg/day, 0.45/1.5 mg/day, and 0.3/1.5 mg/day for 6 months (6 continuous 28-day cycles)
Number of subjects: 1028
Study 18202964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 1028
Study 16363019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 274
Study 16363019 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 274
Study 14653291 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical sealants
Number of subjects: 102
Study 14653291 — intervention group
Group type: COMPARATOR
Intervention: Flowable composites
Number of subjects: 102
Study 14653291 — intervention group
Group type: COMPARATOR
Intervention: Flowable compomers
Number of subjects: 102
Study 14653291 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional etching with phosphoric acid
Number of subjects: 102
Study 14653291 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitating the etchant
Number of subjects: 102
Study 14653291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure types
Number of subjects: 102